Additionally, the 36-month beta value for ACXP is -1.31. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ACXP is 20.39M and currently, short sellers hold a 2.59% ratio of that float. The average trading volume of ACXP on July 01, 2025 was 5.99M shares.
ACXP) stock’s latest price update
Acurx Pharmaceuticals Inc (NASDAQ: ACXP)’s stock price has increased by 18.79 compared to its previous closing price of 0.43. However, the company has seen a -15.22% decrease in its stock price over the last five trading sessions. zacks.com reported 2025-06-18 that Here is how Acurx Pharmaceuticals, Inc. (ACXP) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
ACXP’s Market Performance
Acurx Pharmaceuticals Inc (ACXP) has experienced a -15.22% fall in stock performance for the past week, with a 32.09% rise in the past month, and a 25.07% rise in the past quarter. The volatility ratio for the week is 19.62%, and the volatility levels for the past 30 days are at 14.21% for ACXP. The simple moving average for the past 20 days is 12.72% for ACXP’s stock, with a -46.00% simple moving average for the past 200 days.
ACXP Trading at 22.89% from the 50-Day Moving Average
After a stumble in the market that brought ACXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.64% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACXP starting from Scodari Joseph C, who purchase 24,631 shares at the price of $1.01 back on Jan 06 ’25. After this action, Scodari Joseph C now owns 27,708 shares of Acurx Pharmaceuticals Inc, valued at $25,000 using the latest closing price.
Sailer Carl, the Director of Acurx Pharmaceuticals Inc, purchase 24,631 shares at $1.01 during a trade that took place back on Jan 06 ’25, which means that Sailer Carl is holding 137,183 shares at $25,000 based on the most recent closing price.
Stock Fundamentals for ACXP
The total capital return value is set at 0.0. Equity return is now at value -285.79, with -170.68 for asset returns.
Currently, EBITDA for the company is -14.1 million with net debt to EBITDA at 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.93.
Conclusion
In conclusion, Acurx Pharmaceuticals Inc (ACXP) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
